Gyre Therapeutics Emerges as a Notable Player in Liver Fibrosis Drug Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 26 2025
0mins
Should l Buy MDGL?
Source: Benzinga
Gyre Therapeutics Overview: Gyre Therapeutics Inc. is a biopharmaceutical company focusing on organ fibrosis treatments, with its flagship product ETUARY being the first approved treatment for idiopathic pulmonary fibrosis in China.
Financial Performance: The company reported second-quarter sales of $26.78 million, falling short of expectations, but anticipates revenue growth in 2025 driven by new product launches and existing sales.
Hydronidone Development: Gyre's lead asset, hydronidone, has shown promising results in clinical trials for liver fibrosis and is expected to enter Phase 2 assessment in the U.S. by late 2025, with plans for accelerated approval in China.
Market Potential: Analysts predict significant market potential for hydronidone, estimating it could generate approximately $6 billion in annual sales by 2033, similar to the success anticipated for Madrigal Pharmaceuticals' recent liver disease treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDGL
Wall Street analysts forecast MDGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDGL is 636.22 USD with a low forecast of 527.00 USD and a high forecast of 900.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 463.420
Low
527.00
Averages
636.22
High
900.00
Current: 463.420
Low
527.00
Averages
636.22
High
900.00
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sagimet Stock Increases Following Acne Treatment Success
- Stock Performance: Shares of Sagimet Biosciences increased by up to 12% on Tuesday morning.
- Clinical Trial Results: The rise in stock price was driven by positive results from clinical trials for its acne treatment.
- Analyst Recommendation: Guggenheim Securities issued a new Buy recommendation for Sagimet Biosciences.
- Market Reaction: The combination of clinical success and analyst support contributed to the stock's upward movement.
See More
AIG Stock Drops 10.05% Following Leadership Transition Announcement
- Leadership Transition: American International Group announced CEO Peter Zaffino's planned retirement by mid-2026, resulting in a 10.05% stock drop this week, reflecting market uncertainty regarding future leadership.
- Analyst Rating Adjustment: Barclays analyst Alex Scott maintains an Equal-Weight rating on AIG while lowering the price target from $88 to $81, indicating a cautious outlook on the company's future performance.
- Market Reaction: Following the leadership transition announcement, investor confidence in AIG waned, leading to a decline in its stock price from $75.43, which negatively impacted overall portfolio performance.
- Industry Impact: This stock drop not only affects AIG's market valuation but may also undermine its competitive position in the insurance sector, especially amid increasing leadership uncertainty.
See More
U.S. Markets Finished Higher on Friday; Sandisk Saw Notable Gains
- U.S. Stock Market Performance: Stock indexes in the U.S. experienced gains on Friday, with the overall market rising by 0.81%.
- Index Increases: The S&P 500 increased by 0.65%, while the Dow Jones Industrial Average saw a gain of 0.48%.
See More
Madrigal Secures Exclusive License from Pfizer for Ervogastat with $50M Upfront Payment
- Exclusive License Agreement: Madrigal Pharmaceuticals has secured an exclusive global license from Pfizer for ervogastat, a clinical-stage oral DGAT-2 inhibitor, with an upfront payment of $50 million, thereby strengthening its leadership in MASH therapies.
- Clinical Potential: In a prior Phase 2 study, 72% of patients treated with ervogastat achieved at least a 30% reduction in liver fat, and 61% achieved a 50% reduction, indicating potential additive efficacy when combined with Rezdiffra.
- Future Development Plans: Madrigal plans to conduct a drug-drug interaction study in 2026 and consult with the FDA on the design of a Phase 2 combination trial, further advancing its clinical development of MASH treatment regimens.
- Market Demand: As MASH is a complex disease with increasing patient prevalence, Madrigal's diversified treatment portfolio aims to address the urgent need for multiple therapeutic approaches, enhancing patient outcomes significantly.
See More
Madrigal Pharmaceuticals Downgraded to Hold, Shares Drop Over 5%
- Rating Change: Analyst Andy Chen downgraded Madrigal Pharmaceuticals from outperform to hold with a price target of $572 per share, reflecting concerns over the stock's valuation relative to its performance.
- Stock Volatility: Following the downgrade, Madrigal's shares fell over 5% during the trading session, indicating a decline in market confidence regarding its future growth potential.
- Market Expectations: Despite the FDA's approval of its flagship drug Rezdiffra, the analyst expressed skepticism about Madrigal achieving the anticipated $6 billion in annual revenue, suggesting that the current stock price already reflects its rapid growth expectations.
- Investment Advice: The analyst recommends investors consider other biotech and pharmaceutical stocks, arguing that Madrigal's valuation is too high and may no longer represent an ideal investment opportunity.
See More
Madrigal Pharmaceuticals Downgraded by Wolfe Research, Stock Drops Over 5%
- Rating Downgrade Impact: Wolfe Research analyst Andy Chen downgraded Madrigal's rating from outperform to hold, resulting in a more than 5% drop in stock price during the trading session, indicating market concerns about the company's future performance.
- Price Target Analysis: Chen set a price target of $572 per share, primarily based on the high valuation of Madrigal's stock relative to its performance, reflecting a cautious investor sentiment regarding its growth potential.
- Revenue Expectation Challenges: Despite optimistic projections for Madrigal's Rezdiffra drug, with annual revenue estimates reaching $6 billion, Chen expressed skepticism about this outlook, suggesting that even achieving it would not justify the current high valuation.
- Market Reaction: Madrigal's stock experienced significant gains following the FDA approval of Rezdiffra, but analysts believe this success is already priced in, prompting investors to consider more attractive biotech stocks.
See More
Sagimet Stock Increases Following Acne Treatment Success
- Stock Performance: Shares of Sagimet Biosciences increased by up to 12% on Tuesday morning.
- Clinical Trial Results: The rise in stock price was driven by positive results from clinical trials for its acne treatment.
- Analyst Recommendation: Guggenheim Securities issued a new Buy recommendation for Sagimet Biosciences.
- Market Reaction: The combination of clinical success and analyst support contributed to the stock's upward movement.
See More
AIG Stock Drops 10.05% Following Leadership Transition Announcement
- Leadership Transition: American International Group announced CEO Peter Zaffino's planned retirement by mid-2026, resulting in a 10.05% stock drop this week, reflecting market uncertainty regarding future leadership.
- Analyst Rating Adjustment: Barclays analyst Alex Scott maintains an Equal-Weight rating on AIG while lowering the price target from $88 to $81, indicating a cautious outlook on the company's future performance.
- Market Reaction: Following the leadership transition announcement, investor confidence in AIG waned, leading to a decline in its stock price from $75.43, which negatively impacted overall portfolio performance.
- Industry Impact: This stock drop not only affects AIG's market valuation but may also undermine its competitive position in the insurance sector, especially amid increasing leadership uncertainty.
See More
U.S. Markets Finished Higher on Friday; Sandisk Saw Notable Gains
- U.S. Stock Market Performance: Stock indexes in the U.S. experienced gains on Friday, with the overall market rising by 0.81%.
- Index Increases: The S&P 500 increased by 0.65%, while the Dow Jones Industrial Average saw a gain of 0.48%.
See More
Madrigal Secures Exclusive License from Pfizer for Ervogastat with $50M Upfront Payment
- Exclusive License Agreement: Madrigal Pharmaceuticals has secured an exclusive global license from Pfizer for ervogastat, a clinical-stage oral DGAT-2 inhibitor, with an upfront payment of $50 million, thereby strengthening its leadership in MASH therapies.
- Clinical Potential: In a prior Phase 2 study, 72% of patients treated with ervogastat achieved at least a 30% reduction in liver fat, and 61% achieved a 50% reduction, indicating potential additive efficacy when combined with Rezdiffra.
- Future Development Plans: Madrigal plans to conduct a drug-drug interaction study in 2026 and consult with the FDA on the design of a Phase 2 combination trial, further advancing its clinical development of MASH treatment regimens.
- Market Demand: As MASH is a complex disease with increasing patient prevalence, Madrigal's diversified treatment portfolio aims to address the urgent need for multiple therapeutic approaches, enhancing patient outcomes significantly.
See More
Madrigal Pharmaceuticals Downgraded to Hold, Shares Drop Over 5%
- Rating Change: Analyst Andy Chen downgraded Madrigal Pharmaceuticals from outperform to hold with a price target of $572 per share, reflecting concerns over the stock's valuation relative to its performance.
- Stock Volatility: Following the downgrade, Madrigal's shares fell over 5% during the trading session, indicating a decline in market confidence regarding its future growth potential.
- Market Expectations: Despite the FDA's approval of its flagship drug Rezdiffra, the analyst expressed skepticism about Madrigal achieving the anticipated $6 billion in annual revenue, suggesting that the current stock price already reflects its rapid growth expectations.
- Investment Advice: The analyst recommends investors consider other biotech and pharmaceutical stocks, arguing that Madrigal's valuation is too high and may no longer represent an ideal investment opportunity.
See More
Madrigal Pharmaceuticals Downgraded by Wolfe Research, Stock Drops Over 5%
- Rating Downgrade Impact: Wolfe Research analyst Andy Chen downgraded Madrigal's rating from outperform to hold, resulting in a more than 5% drop in stock price during the trading session, indicating market concerns about the company's future performance.
- Price Target Analysis: Chen set a price target of $572 per share, primarily based on the high valuation of Madrigal's stock relative to its performance, reflecting a cautious investor sentiment regarding its growth potential.
- Revenue Expectation Challenges: Despite optimistic projections for Madrigal's Rezdiffra drug, with annual revenue estimates reaching $6 billion, Chen expressed skepticism about this outlook, suggesting that even achieving it would not justify the current high valuation.
- Market Reaction: Madrigal's stock experienced significant gains following the FDA approval of Rezdiffra, but analysts believe this success is already priced in, prompting investors to consider more attractive biotech stocks.
See More
